Strengthened balance sheet with successful completion of upsized $168.3 million initial public offering

Announced FDA Fast Track designation for BH-30643 for the treatment of advanced
EGFR C797S-positive NSCLC

SAN DIEGO, Sept. 18, 2026 (GLOBE NEWSWIRE) — BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced financial results for the second quarter 2026 and highlighted recent progress.

“We’ve achieved meaningful progress across our pipeline, as well as our significant corporate milestones, since the beginning of the second quarter,” said Jean Cui, Ph.D., Founder, President and Chief Executive Officer of BlossomHill Therapeutics. “In April, we presented our first preclinical data from our pseudo-irreversible pan-KRAS inhibitor BH-501284, built on a novel chemical scaffold, at AACR where we highlighted the sustained target engagement leading to tumor regression at low dose levels. At ASCO in early June we presented the preliminary safety, PK and antitumor activities of BH-30643 in Phase 1 dose escalation of the SOLARA trial, along with the initial efficacy data in C797S-positive NSCLC. More recently we announced that BH-30643 received Fast Track designation, an important regulatory milestone that reflects the FDA’s recognition of the potential for this molecule. We also presented encouraging safety data and early signs of anti-leukemic activity observed with BH-30236, our novel macrocyclic CLK inhibitor, both as a monotherapy and in combination with venetoclax, at EHA in the middle of June. We are now looking forward to our end-of-phase 1 meeting with the FDA later this year. With a strong balance sheet following our successful initial public offering in August, we believe we are well positioned to deliver important clinical and regulatory milestones over the coming quarters as we continue advancing our intentionally designed medicines that address significant unmet medical needs in cancer treatment.”

Recent Business Highlights and Corporate Updates:

  • Strengthened the balance sheet with approximately $168.3 million in gross proceeds from the initial public offering (IPO) in August 2026
  • Announced the U.S. Food and Drug Administration (FDA) granted Fast Track designation to BH-30643, a macrocyclic OMNI-EGFR™ inhibitor, for the treatment of adult patients with advanced or metastatic epidermal growth factor receptor (EGFR) C797S-positive non-small cell lung cancer (NSCLC) after prior treatment with a third-generation EGFR tyrosine kinase inhibitor (TKI)
  • Presented preliminary results of BH-30643 from dose escalation and backfill cohorts in the ongoing Phase 1/2 SOLARA trial in advanced or metastatic EGFR-mutant NSCLC at the American Society of Clinical Oncology (ASCO) 2026 annual meeting, and additional follow up data at IASLC 2026 World Conference on Lung Cancer, which highlighted a 45% objective response rate and 88% disease control rate observed in patients with C797S resistance to prior TKIs, with or without concurrent T790M mutation
  • Presented the first preclinical data from the pseudo-irreversible pan-KRAS inhibitor BH-501284, built on a novel chemical scaffold, at the American Association for Cancer Research (AACR) 2026 annual meeting
  • Presented initial clinical data from the ongoing first-in-human Phase 1/1b trial of BH-30236, an orally bioavailable, macrocyclic CDC-like kinase (CLK) inhibitor, in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS) at the European Hematology Association (EHA) 2026 Congress
  • Expanded the Company’s Board of Directors with the appointments of Sheila Gujrathi, M.D., and John Schmid

Anticipated Upcoming Milestones:
BH-30643

  • Q4 2026: End of Phase 1 meeting regarding a recommended Phase 2 dose selection and a potential accelerated approval pathway in C797S resistance
  • Q1 2027: First patient dosed in anticipated pivotal Phase 2 trial
  • 1H 2027: Updated Phase 1 data, including C797S durability
  • 2H 2027: Updated Phase 1 data on TKI-naive durability and initial chemo combo cohort data

BH-501284

  • Q1 2027: Investigational New Drug submission

BH-30236  

  • 1H 2027: Updated Phase 1 data on safety and anti-leukemic effect

Second Quarter 2026 Financial Results

Research and development (R&D) expenses for the second quarter of 2026 were $21.4 million, compared with $12.5 million for the same period in 2025. The increase was primarily due to greater clinical development expenses driven by the SOLARA trial, expenses to support IND-enabling studies for BH-501284, and greater costs related to personnel, facilities and other overhead.

General and administrative (G&A) expenses for the second quarter of 2026 were $3.3 million, compared with $1.6 million for the same period in 2025. The increase was primarily due to greater legal expenses, personnel-related expenses and overhead.

Net loss for the second quarter of 2026 was $23.8 million, or $(8.75) per basic and diluted share, compared with a net loss of $13.2 million, or $(5.51) per basic and diluted share for the same period in 2025. The increase in net loss was primarily attributable to increased operating expenses.

Cash and cash equivalents totaled $95.4 million as of June 30, 2026. BlossomHill subsequently completed its IPO in August 2026 in which it sold 10,516,240 shares of its common stock, including partial exercise of the over-allotment option, for gross proceeds of $168.3 million. BlossomHill believes that its cash and cash equivalents as of June 30, 2026, together with the proceeds from its IPO, will be sufficient to fund its operations into the second quarter of 2028.

About BH-30643
BH-30643 is an investigational, novel, orally bioavailable, non-covalent, macrocyclic, brain active, mutant-selective, OMNI-EGFR™ inhibitor for the treatment of EGFR-mutant NSCLC. BH-30643 was designed to overcome the limitations of currently approved EGFR inhibitors, which were discovered over a decade ago without the current, modern understanding of the structure and protein dynamics of mutant EGFRs. In preclinical studies, BH-30643 demonstrated potent inhibitory activity across diverse EGFR mutation categories – classical mutations, on-target resistance mutations such as C797S with or without T790M, atypical mutations and exon 20 insertions – while maintaining marked selectivity over wild-type EGFR. BH-30643 has received Fast Track designation and is being evaluated in SOLARA, a global Phase 1/2, first-in-human clinical trial spanning more than 40 sites in 10 countries. Ongoing dose expansion cohorts are enrolling in both TKI-pretreated and TKI-naive settings, including a C797S resistance cohort. For additional information on SOLARA, including a list of study sites and how to enroll, please visit clinicaltrials.gov (NCT06706076).

About BH-30236
BH-30236 is an investigational orally bioavailable, macrocyclic inhibitor of the CDC-like kinase (CLK) family. BH-30236 was intentionally designed to potently inhibit CLK, leading to modulation of aberrant alternative splicing in cancerous tissue, targeting the same aberrant splicing machinery that drives relapsed or refractory (R/R) acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS) disease biology and that cancer cells exploit to develop resistance to venetoclax, FLT3 inhibitors and cytarabine.   BH-30236 is being evaluated in a Phase 1/1b multicenter, open-label, first-in-human dose escalation and expansion trial in adults with R/R AML and HR-MDS. The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to BH-30236 for the treatment of AML. For additional information on this trial, including a list of study sites and how to enroll, please visit clinicaltrials.gov (NCT06501196).

About BH-501284
BH-501284 is an investigational, orally bioavailable pan-KRAS inhibitor, which utilizes a novel Switch-II chemical scaffold to achieve prolonged, potent and selective inhibition of KRAS mutations. We believe this molecule, which uses a non-covalent scaffold, is unique in its potential to achieve tight and durable binding, a feature described as “pseudo-irreversible” binding. In preclinical studies, BH-501284 has achieved pseudo-irreversible binding characteristics with high binding affinity, while maintaining high selectivity for KRAS.

About BlossomHill Therapeutics
BlossomHill Therapeutics, Inc. is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines that address significant unmet medical needs in cancer treatment. Founded and led by industry veteran J. Jean Cui, Ph.D., with her proven track record in oncology drug design and development – including three FDA-approved drugs – BlossomHill Therapeutics applies cutting-edge science with a goal to address key oncogenic drivers and improve patient outcomes in difficult-to-treat cancers. The company’s lead clinical program is BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFRTM inhibitor for the treatment of EGFR-mutant non-small cell lung cancer (NSCLC), which has received Fast Track designation for the C797S resistance population after 3rd generation EGFR TKI treatment. The company is also conducting clinical development of BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor initially being studied in a clinical trial for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS). The company’s pipeline also includes BH-501284, a preclinical, non-covalent, selective, pan-KRAS Switch-II inhibitor for potential future development in diverse KRAS-mutant tumors.

BlossomHill Therapeutics is headquartered in San Diego, California. For more information, visit bhtherapeutics.com and follow us on LinkedIn and X.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other federal securities laws, including, without limitation, statements regarding: the therapeutic potential, clinical benefits, safety and potential competitive differentiation of the company’s product candidates, including BH-30643, BH-30236 and BH-501284; the anticipated benefits of regulatory designations received, or that may be received, by the company’s product candidates; the design, enrollment, timing, progress and results of the company’s clinical trials and preclinical studies; the company’s planned regulatory interactions and submissions; anticipated program milestones, including the timing of program and data updates; the period over which the company estimates its existing cash and cash equivalents, together with the net proceeds from its initial public offering, will be sufficient to fund its current operating plan; statements by the company’s management; and the company’s development plans and continued advancement of its pipeline. The words “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “upcoming,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially, including, without limitation: the company’s limited operating history, history of significant losses and the early stage of development of its product candidates; the risk that preliminary and interim clinical data are subject to further analysis and may not be predictive of, may be inconsistent with, or may be more favorable than, data generated as clinical trials continue or data from future clinical trials; uncertainties inherent in the initiation, timing, design and enrollment of clinical trials, and the availability and timing of data from ongoing and future trials; the company’s ability to successfully demonstrate the safety and efficacy of its product candidates and to obtain and maintain regulatory approvals; the timing and outcome of planned interactions with, and submissions to, the FDA and other regulatory authorities, including whether an accelerated approval pathway will be available to the company; the risk that regulatory designations, including Fast Track and orphan drug designation, may not result in a faster development, review or approval process, may not increase the likelihood of regulatory approval, and may be withdrawn; competition from third parties that are developing products for similar indications; the prior success of the company’s management team may not be indicative of future success; the company’s reliance on third parties, including contract research organizations and contract manufacturing organizations; the company’s ability to obtain, maintain and protect its intellectual property; and the company’s need for additional financing and its estimates regarding operating expenses and capital requirements. These and other risks are described in greater detail under the heading “Risk Factors” in the company’s filings with the Securities and Exchange Commission (the “SEC”), its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, which will be filed with the SEC later today, as well as in the company’s subsequent filings with the SEC. Any forward-looking statements represent the company’s views only as of the date of this press release, and the company expressly disclaims any obligation to update any forward-looking statements, except as required by law.

Company Contact:
Michael Moore, BlossomHill Therapeutics
michael.moore@bhtherapeutics.com

Media:
Ashlea Kosikowski, 1AB
ashlea@1abmedia.com

BLOSSOMHILL THERAPEUTICS, INC.
UNAUDITED CONDENSED BALANCE SHEETS
(in thousands, except share and par value data)
             
    June 30, 2026     December 31, 2025
    (unaudited)        
Assets        
Current Assets:        
Cash and cash equivalents   $ 95,376     $ 136,682  
Prepaid expenses and other current assets     5,592       2,144  
Total current assets     100,968       138,826  
Property and equipment, net     1,489       1,726  
Operating lease right-of-use assets     19,197       19,921  
Other assets     2,477       2,495  
Total assets   $ 124,131     $ 162,968  
Liabilities, convertible preferred stock and stockholders’ deficit        
Current liabilities:        
Accounts payable   $ 3,930     $ 2,314  
Accrued expenses     9,194       8,431  
Accrued compensation     3,539       4,730  
Other current liabilities     809       –  
Operating lease liability, current     1,149       5  
Total current liabilities     18,621       15,480  
Operating lease liability, non-current     22,222       22,393  
Other long-term liabilities     1,245       –  
Total liabilities     42,088       37,873  
Convertible preferred stock, $0.0001 par value; 85,552,612 shares
authorized at June 30, 2026 and December 31, 2025; 18,258,960
shares issued and outstanding at June 30, 2026 and December 31,
2025; $257,153 aggregate liquidation preference at June 30, 2026
and December 31, 2025
    256,823       256,823  
Stockholders’ deficit:        
Common stock, $0.0001 par value; 110,000,000 shares authorized
at June 30, 2026 and December 31, 2025; 2,767,848 and 2,548,659
shares issued and outstanding as of June 30, 2026
and December 31, 2025, respectively
    1       1  
Additional paid-in capital     5,014       3,300  
Accumulated deficit     (179,795)       (135,029)  
Total stockholders’ deficit     (174,780)       (131,728)  
Total liabilities, convertible preferred stock and stockholders’ deficit   $ 124,131     $ 162,968  

BLOSSOMHILL THERAPEUTICS, INC.
UNAUDITED CONDENSED STATEMENTS OF OPERATIONS
(in thousands, except share and per share data)
             
    Three Months Ended June 30,     Six Months Ended June 30,  
    2026     2025     2026     2025  
Operating expenses:                        
Research and development   $ 21,355     $ 12,530     $ 41,256     $ 22,102  
General and administrative     3,315       1,573       5,521       3,455  
Total operating expenses     24,670       14,103       46,777       25,557  
Loss from operations     (24,670 )     (14,103 )     (46,777 )     (25,557 )
Other income (expense), net:                        
Interest income, net     915       859       2,017       1,835  
Other expense, net     (3 )     –       (6 )     –  
Total other income, net     912       859       2,011       1,835  
Net loss   $ (23,758 )   $ (13,244 )   $ (44,766 )   $ (23,722 )
Net loss per share, basic and diluted   $ (8.75 )   $ (5.51 )   $ (16.91 )   $ (9.90 )
Weighted average common shares outstanding, basic and diluted     2,713,696       2,405,140       2,646,721       2,395,789  

Cambria Gold Mines Inc. joins over 20 companies from Michael Gentile’s portfolio at the inaugural Forum on October 19, 2026, in Mayfair, London

VANCOUVER, British Columbia, Sept. 18, 2026 (GLOBE NEWSWIRE) — Cambria Gold Mines Inc. (TSXV: CAMB; OTCQX: CAMVF) today announced its participation in the inaugural Gentile Mining Investor Forum, a full-day investor conference in London on Monday, October 19, 2026, at 116 Pall Mall in Mayfair. The program is presented by strategic junior mining investor Michael Gentile in partnership with Amvest Capital Inc. (“Amvest Capital”), and made possible by the generous support of Flagship Sponsors ATB Cormark Capital Markets, Beacon Securities Limited, and STIFEL. Full program details and registration are available at gentileminingroadshow.com.

“I created this program to give serious investors direct, in-person access to a select group of companies I’ve backed with conviction. Each one represents what I believe to be a high-potential opportunity in the mining sector. These are names I have researched deeply, invested in personally, and believe have the potential to deliver meaningful value. Amvest Capital has been an outstanding partner in building a week of events that meets the standards these investors and companies deserve,” said Michael Gentile.

The Forum will bring together up to 150 investors, family offices, wealth managers, and sector-focused high-net-worth individuals for a full day of structured one-on-one meetings and dedicated issuer showcases alongside over 20 companies from Gentile’s portfolio, including Cambria Gold Mines Inc. The day opens with a keynote breakfast featuring Michael Gentile, presented by session sponsor Canaccord Genuity, followed by issuer showcases presented by TSX and TSX Venture Exchange, an executive lunch and speaker panel, and an all-day investor lounge and networking reception hosted by session sponsor Investor. Events. Crux Investor serves as the Forum’s media sponsor.

“Our team has spent years building relationships with resource investors across North and South America, Europe, and Asia. This program puts that network to work, giving these companies direct access to a global base of qualified investors in a single room,” said Gabriel Alonso-Mendoza, Co-Founder and Managing Partner of Amvest Capital. “Michael’s conviction and hands-on approach to these companies fit perfectly with our firm’s philosophy. We are thrilled to once again partner with Michael and his portfolio companies.”

Register Now

Investor registration is now open. Investor attendance is free of charge; registrations are reviewed prior to confirmation. Space is limited, and meetings are allocated on a first-confirmed basis. Full program details and registration are available at gentileminingroadshow.com.

About Cambria Gold Mines Inc.

Cambria is advancing a focused redevelopment of a legacy gold mining complex in British Columbia’s Golden Triangle. By aligning high-grade geology, existing infrastructure, and experienced leadership, Cambria is positioned to move methodically toward sustainable, long-life production.

This is an execution-driven opportunity built on what already exists — permitted assets, substantial investment, and a clear development pathway — guided by a team with direct experience restarting complex mining operations.

About Michael Gentile

Michael Gentile is widely recognized as a leading strategic investor in the junior mining sector. He began his investing career in 2002 at Formula Growth Limited, where he spent 17 years, and from 2012 to 2018 co-managed one of Canada’s largest market-neutral hedge funds alongside his partner, Charles Haggar. In 2022 he co-founded Bastion Asset Management, a Montreal-based investment firm that manages more than CAD $900 million in small and mid-cap equities across the United States and Canada. Since 2018 he has applied a disciplined, portfolio-based approach to junior mining, and today holds top shareholder positions in 35 companies in the sector and serves on six boards.

About Amvest Capital

Amvest Capital is a New York-based investment bank and funds management firm focused solely on natural resources. The firm partners with companies and management teams to develop and finance high-quality natural resource assets worldwide, combining disciplined capital allocation with strategic advisory expertise to advance responsible and sustainable resource development. As part of its business, Amvest Capital conducts investor roadshows across North America, Europe, Australia, and beyond for NYSE, TSX, TSX-V, ASX, and LSE-listed clients, with deep relationships across the institutional investor community in global markets. Learn more at amvestcapital.com.

For more information, please contact:

Sam Brezden
Email: sam.brezden@cambriagold.com
Phone: 236-838-1840

Cautionary Statements:

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Cautionary Statement Regarding Forward-Looking Information

All statements and other information contained in this press release about anticipated future events may constitute forward-looking information under Canadian securities laws (“forward-looking statements”). Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “targeted”, “outlook”, “on track” and “intend” and statements that an event or result “may”, “will”, “should”, “could”, “would” or “might” occur or be achieved and other similar expressions. All statements, other than statements of historical fact, included herein are forward-looking statements, including the timing, positioning and completion of the construction on the access road; the future commencement of trucking of production at the Premier Mine; the timing and successful completion of an updated Feasibility Study incorporating all four deposits by Q4 2026; the timing and completion of the fisheries offset work; the ability of the Company to accomplish its business objectives and the intentions described herein; and future plans, development and operations of the Company. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements, risks relating to negative operating cash flows of the Company; business and economic conditions in the mining industry generally; fluctuations in commodity prices and currency exchange rates; environmental compliance; risks related to outstanding debt; uncertainty of estimates and projections relating to development, production, costs and expenses, and health, safety and environmental risks; uncertainties relating to interpretation of drill results and the geology, continuity and grade of mineral deposits; the need to obtain additional financing to finance operations and uncertainty as to the availability and terms of future financing; social media and reputation; negative publicity; human rights; business objectives; shortage of personnel; health and safety; the possibility of delay in future plans and uncertainty of meeting anticipated program milestones; claims and legal proceedings; information systems and cyber security; internal controls; violation of anti-bribery or corruption laws; competition; tax considerations; compliance with listing standards; enforcement of civil liabilities; financing requirement risks; market price volatility of the common shares; uncertainty as to timely availability of permits and other governmental approvals; the need for exchange approval, and other regulatory approvals and other risk factors as detailed from time to time in Cambria’s filings with Canadian securities regulators, available on Cambria’s profile on SEDAR+ at www.sedarplus.ca. Forward-looking statements are based on assumptions made with regard to: the estimated costs associated with the care and maintenance plans; the tax rate applicable to the Company; future commodity prices; the grade of mineral resources and mineral reserves; labor and materials costs increasing on a basis consistent with the Company’s current expectations, the ability of the Company to convert inferred mineral resources to other categories; the ability of the Company to reduce mining dilution; the ability to reduce capital costs; the ability of the Company to raise additional financing; currency exchange rates being approximately consistent with current levels, compliance with the covenants in Cambria’s credit agreements; exploration plans; and general marketing, political, business and economic conditions. Forward-looking statements are based on estimates and opinions of management at the date the statements are made. Although Cambria believes that the expectations reflected in such forward-looking statements and/or information are reasonable, undue reliance should not be placed on forward-looking statements since Cambria can give no assurance that such expectations will prove to be correct. Cambria does not undertake any obligation to update forward-looking statements, other than as required by applicable laws. The forward-looking information contained in this press release is expressly qualified by this cautionary statement.

Leviathan Metals joins over 20 companies from Michael Gentile’s portfolio at the inaugural Forum on October 19, 2026, in Mayfair, London

VANCOUVER, British Columbia, Sept. 18, 2026 (GLOBE NEWSWIRE) — Leviathan Metals Corp. (“Leviathan”, the “Company”) (LVX – TSXV, LVXFF – OTC, 0GP – FSE) today announced its participation in the inaugural Gentile Mining Investor Forum, a full-day investor conference in London on Monday, October 19, 2026, at 116 Pall Mall in Mayfair. The program is presented by strategic junior mining investor Michael Gentile in partnership with Amvest Capital Inc. (“Amvest Capital”), and made possible by the generous support of Flagship Sponsors ATB Cormark Capital Markets, Beacon Securities Limited, and STIFEL. Full program details and registration are available at gentileminingroadshow.com.

“I created this program to give serious investors direct, in-person access to a select group of companies I’ve backed with conviction. Each one represents what I believe to be a high-potential opportunity in the mining sector. These are names I have researched deeply, invested in personally, and believe have the potential to deliver meaningful value. Amvest Capital has been an outstanding partner in building a week of events that meets the standards these investors and companies deserve,” said Michael Gentile.

The Forum will bring together up to 150 investors, family offices, wealth managers, and sector-focused high-net-worth individuals for a full day of structured one-on-one meetings and dedicated issuer showcases alongside over 20 companies from Gentile’s portfolio, including Leviathan Metals Corp. The day opens with a keynote breakfast featuring Michael Gentile, presented by session sponsor Canaccord Genuity, followed by issuer showcases presented by TSX and TSX Venture Exchange, an executive lunch and speaker panel, and an all-day investor lounge and networking reception hosted by session sponsor Investor.Events. Crux Investor serves as the Forum’s media sponsor.

“Our team has spent years building relationships with resource investors across North and South America, Europe, and Asia. This program puts that network to work, giving these companies direct access to a global base of qualified investors in a single room,” said Gabriel Alonso-Mendoza, Co-Founder and Managing Partner of Amvest Capital. “Michael’s conviction and hands-on approach to these companies fit perfectly with our firm’s philosophy. We are thrilled to once again partner with Michael and his portfolio companies.”

Register Now

Investor registration is now open. Investor attendance is free of charge; registrations are reviewed prior to confirmation. Space is limited, and meetings are allocated on a first-confirmed basis. Full program details and registration are available at gentileminingroadshow.com.

About Leviathan Metals Corp.

Leviathan Metals Corp., is a Canadian-based mineral exploration company listed on the TSXV (LVX), Germany (0GP) and OTC (LVXFF). Our flagship property is the Central Project within Botswana’s world-class Kalahari Copper Belt (the ‘KCB’), over which we enjoy 100% ownership, and at which drilling is under way. The Central Project immediately adjoins MMG’s world-class Khoemacau copper-silver cluster, a district-scale system that MMG acquired for approximately US$1.9 billion. This portfolio is complemented by the Serule uranium property, also in Botswana and adjacent to Lotus Resources’ Letlhakane project, as well at the Foča silver-lead-zinc project in Bosnia and Herzegovina, where historic drilling and recent trenching each returned high-grade mineralization. With a strong treasury, active drilling in Botswana, and a strategic prospective land position in one of the world’s most prospective emerging copper belts, Leviathan is positioned for success.

Botswana is a politically stable pro-mining investment jurisdiction – ranked #2 in Africa by the Fraser Institute (2024), enjoying investor-friendly legislation, a highly proficient and well-educated workforce, and first world infrastructure – set up to support mining, which is a pivotal and widely-accepted national economic driver.

About Michael Gentile

Michael Gentile is widely recognized as a leading strategic investor in the junior mining sector. He began his investing career in 2002 at Formula Growth Limited, where he spent 17 years, and from 2012 to 2018 co-managed one of Canada’s largest market-neutral hedge funds alongside his partner, Charles Haggar. In 2022 he co-founded Bastion Asset Management, a Montreal-based investment firm that manages more than CAD $900 million in small and mid-cap equities across the United States and Canada. Since 2018 he has applied a disciplined, portfolio-based approach to junior mining, and today holds top shareholder positions in 35 companies in the sector and serves on six boards.

About Amvest Capital

Amvest Capital is a New York-based investment bank and funds management firm focused solely on natural resources. The firm partners with companies and management teams to develop and finance high-quality natural resource assets worldwide, combining disciplined capital allocation with strategic advisory expertise to advance responsible and sustainable resource development. As part of its business, Amvest Capital conducts investor roadshows across North America, Europe, Australia, and beyond for NYSE, TSX, TSX-V, ASX, and LSE-listed clients, with deep relationships across the institutional investor community in global markets. Learn more at amvestcapital.com.

For more information, please contact:

Luke Norman, Chief Executive Officer and Director
Toll Free: 1-888-875-8832
Email: info@leviathanmetals.com

For further information, please visit the Company website www.leviathanmetals.com and the Company’s profile on SEDAR+ at www.sedarplus.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. No securities regulatory authority has either approval or disapproved of the contents of this press release.

POMPANO BEACH, Fla., Sept. 18, 2026 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced it has entered into a $40 million Committed Equity Facility (the “CEF”) with Roth Principal Investments, LLC (“Roth”), an affiliate of CR Financial Holdings, Inc., the holding company for Roth Capital Partners.

The CEF allows, but does not obligate, BioStem to issue and sell up to $40 million of shares of its common stock (the “Shares”) to Roth, at BioStem’s sole discretion by way of a private placement and subject to certain conditions set forth in the CEF common stock purchase agreement (the “Purchase Agreement”), following the filing and effectiveness of a registration statement registering the resale of such shares. Subject to certain specified exceptions, under the applicable Nasdaq rules, the Company may not issue to Roth under the Purchase Agreement a number of Shares which is in excess of 19.99% of the Shares outstanding immediately prior to the execution of the Purchase Agreement (the “Exchange Cap”), unless the Company obtains shareholder approval to issue the Shares in excess of such Exchange Cap or the average price per Share paid by Roth for all Shares issued under the Purchase Agreement equals or exceeds the applicable minimum price under Nasdaq rules.

BioStem intends to use any net proceeds for working capital and general corporate purposes. BioStem may access capital opportunistically over time and is under no obligation to utilize the full amount available under the CEF.

Pursuant to the registration rights agreement entered into by the Company and Roth in connection with the Purchase Agreement, the Company intends to file a registration statement with the U.S. Securities and Exchange Commission to register the resale by Roth of the Shares issuable under the Purchase Agreement. These securities may not be resold until the registration statement is filed and becomes effective.

No Offer or Solicitation: This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

Forward-Looking Statements: Except for statements of historical fact, this press release also contains forward-looking statements. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements may be identified using words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate”, “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements in this press release include, without limitation, statements regarding the timing and amount of any draws under the $40 million CEF, including the filing and effectiveness of the related registration statement; and the Company’s plans for the use of proceeds from the CEF.

Forward-looking statements are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. These factors include, but are not limited to: the risk that the U.S. Securities and Exchange Commission may not declare effective the registration statement relating to the CEF, or may not do so when expected or at all, limiting or delaying the Company’s access to that facility; the risk that market conditions, the trading price and volume of the Company’s common stock, or the Company’s own discretion may limit the Company’s ability or willingness to draw on the CEF, and the potential dilution to existing stockholders resulting from any such draws; the Company’s ability to extinguish or refinance existing debt as planned; the risk that the Company may be unable to raise additional funds to expand its business; the adequacy of the Company’s capital resources and liquidity to fund its operations and planned commercial expansion; the competition that the Company faces, which could adversely affect its business, results of operations and financial condition; rapid technological change could cause the Company’s products to become obsolete and if the Company does not enhance its product offerings through its research and development efforts, it may be unable to effectively compete; the Company’s ability to convince physicians that its products are safe and effective alternatives to existing treatments and that its products should be used in their procedures; changes in applicable laws or regulations; the risk that the Company may be unable to maintain compliance with Nasdaq’s continued listing standards; the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; and the other risks and uncertainties described under “Risk Factors” in the Company’s Form 10 registration statement and its subsequent filings with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Although it may voluntarily do so from time to time, the Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.

About BioStem Technologies, Inc. (Nasdaq: BSEM): BioStem Technologies, Inc. is a publicly traded, biomedical innovator, focused on developing, manufacturing and commercializing advanced allograft solutions derived from perinatal tissue. The company leverages its industry-leading proprietary BioRetain®, CryoTek® and SteriTek® processing technologies, designed to optimize the preservation of the natural properties of these tissues, supporting their use in clinical settings. Its allografts are used by clinicians across a wide range of specialties. With a growing portfolio of products, expanding clinical research initiatives, and a national commercial footprint, BioStem is committed to advancing innovation in regenerative medicine.

BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB”). These systems and procedures are established in compliance with current Good Tissue Practices (“cGTP”) and current Good Manufacturing Practices (“cGMP”). BioStem’s portfolio of quality brands includes its Neox®, Clarix®, VENDAJE® and American Amnion™ product lines.

Investor Relations:
Philip Trip Taylor, Gilmartin
ir@biostemtech.com

PRINCETON JUNCTION, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) — MISTRAS Group, Inc. (NYSE: MG) (“MISTRAS” or the “Company”), a global leader in technology-enabled industrial asset integrity and laboratory testing solutions, today announced that it had entered into a definitive agreement to be acquired by affiliates of H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with $75 billion of capital under management, in an all-cash transaction, representing an enterprise value of approximately $866 million, including outstanding debt.

Under the terms of the agreement, MISTRAS stockholders will receive $20.35 per share in cash for each share of common stock they own. The purchase price represents a premium of approximately 8% and 13% to the Company’s 30 and 90-day volume-weighted average share price, respectively, for the period ended September 17, 2026. In addition, the purchase price is inclusive of 61% price appreciation since December 31, 2025.

“Upon completion of the transaction, the agreement with H.I.G. would deliver immediate and certain cash value to stockholders,” said Manuel N. Stamatakis, Executive Chairman of MISTRAS’ Board of Directors. “Following extensive engagement with H.I.G., the Board is confident that this agreement is in the best interests of our stockholders and our Company. With H.I.G.’s partnership and support, we believe MISTRAS will be even better positioned to build on the momentum our teams have been delivering through their focus on execution and operational excellence.”

“We are pleased to reach this exciting milestone in our company’s journey to become a leading integrated integrity and testing platform,” said Natalia Shuman, President and Chief Executive Officer of MISTRAS. “H.I.G.’s confidence in our business validates the work we have done through our Vision2030 transformation to deepen the ways we serve our existing customers, expand into new, high-growth end markets and drive efficiency across our organization. We have created significant value through strong execution and we are excited to crystallize that value and work with H.I.G. to continue to invest in our people, drive innovation across our portfolio and broaden our reach to help more customers protect and maintain critical assets.”

“We are very excited by the success achieved by Natalia and the MISTRAS team,” said Matt Gullen, Managing Director at H.I.G. “Through our experience partnering with industrial services businesses, we have developed a deep appreciation for the technical expertise, reliability and customer focus required to support mission-critical operations. MISTRAS has built an impressive platform supported by a highly skilled workforce and longstanding customer relationships, and we look forward to bringing H.I.G.’s experience and resources to support the Company’s next phase of growth.”

Transaction Details

The Company’s Board of Directors has unanimously approved the transaction, which is expected to close in late 2026 or early 2027, subject to customary closing conditions, including approval by the Company’s stockholders and the receipt of required regulatory approvals.

H.I.G. affiliates have entered into voting and support agreements with holders of approximately 31% of the Company’s common stock, under which these stockholders have agreed to vote all owned shares in favor of the transaction.

The definitive agreement includes a 40-day “go-shop” period, expiring at 11:59 p.m. Eastern Time on October 27, 2026, during which time the Company’s Board of Directors, with the assistance of its financial advisor Baird, are permitted to actively initiate, solicit and consider alternative acquisition proposals from third parties. The Company will have the right to terminate the H.I.G. agreement to enter into a superior proposal subject to payment of a termination fee to H.I.G. affiliates and other terms and conditions of such agreement. There can be no assurance that this “go-shop” process will result in a superior proposal or that any other transaction will be approved or completed. The Company does not intend to disclose developments with respect to the go-shop process unless and until its Board of Directors determines such disclosure is required or is otherwise appropriate.

Upon completion of the transaction, the Company’s common stock will no longer be listed on the New York Stock Exchange.

Advisors

Baird is serving as financial advisor to the Company, and Morgan, Lewis & Bockius LLP and Troutman Pepper Locke LLP are serving as legal counsel to the Company.

Texas Capital Securities is serving as financial advisor to H.I.G., and Kirkland & Ellis LLP is serving as legal counsel to H.I.G.

About MISTRAS Group, Inc.
MISTRAS Group, Inc. (NYSE: MG) is a global leader in technology-enabled industrial asset integrity and laboratory testing solutions, serving critical strategic markets including oil & gas, aerospace & defense, industrials, power generation & transmission, infrastructure, engineering, and research. MISTRAS Group provides a diversified portfolio of products and services, ranging from advanced non-destructive testing and pipeline inspections to real-time condition monitoring, maintenance planning, and specialized engineering, powered by a proprietary management software suite that centralizes integrity data for predictive analytics and benchmark analysis. With a long-standing track record of innovation and deep industry expertise, MISTRAS Group helps clients reduce risk, extend asset life, and optimize operational performance. Learn more at www.mistrasgroup.com

About H.I.G. Capital
H.I.G. is a leading global alternative investment firm with $75 billion of capital under management.* Based in Miami, and with offices in Atlanta, Boston, Chicago, Los Angeles, New York, San Francisco, and Stamford in the United States, as well as international affiliate offices in Hamburg, London, Luxembourg, Madrid, Milan, Paris, Bogotá, Rio de Janeiro, Dubai, and Hong Kong, H.I.G. specializes in providing both debt and equity capital to middle market companies, utilizing a flexible and operationally focused/value-added approach. Since its founding in 1993, H.I.G. has invested in and managed more than 400 companies worldwide. The Firm’s current portfolio includes more than 100 companies with combined sales in excess of $53 billion. For more information, please refer to the H.I.G. website at hig.com.
* Based on total capital raised by H.I.G. Capital and its affiliates.

Additional Information Regarding the Proposed Transaction and Where to Find It

In connection with the proposed transaction between the Company and H.I.G., the Company will file with the Securities and Exchange Commission (the “SEC”) a preliminary proxy statement on Schedule 14A relating to a special meeting of its stockholders, which will be announced as promptly as practicable to seek Company stockholder approval in connection with the proposed transaction. Additionally, the Company expects to file a definitive proxy statement on Schedule 14A and other relevant materials with the SEC in connection with the proposed transaction. INVESTORS AND SECURITYHOLDERS OF THE COMPANY ARE URGED TO READ THE PRELIMINARY AND DEFINITIVE PROXY STATEMENTS AND ANY OTHER RELEVANT MATERIALS FILED OR THAT WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE MATERIALS AND DOCUMENTS INCORPORATED BY REFERENCE THEREIN, CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND RELATED MATTERS. Following the filing of the definitive proxy statement with the SEC, the Company will mail the definitive proxy statement and a proxy card to each stockholder entitled to vote at the special meeting relating to the proposed transaction. Any vote in respect of resolutions to be proposed at the Company’s stockholder meeting to approve the proposed transaction or other responses in relation to the proposed transaction should be made only on the basis of the information contained in the proxy statement. Investors and securityholders will be able to obtain free copies of the proxy statement (when available) and other documents filed or that will be filed by the Company with the SEC at http://www.sec.gov, the SEC’s website, or on the Company’s investor relations website (http://www.investors.mistrasgroup.com). In addition, the proxy statement and other documents filed or that will be filed by the Company with the SEC may be obtained from the Company free of charge by requesting them from Investor Relations by email at investors@mistrasgroup.com, or by telephone at 1 (833) MISTRAS.

Participants in the Solicitation

The Company and certain of its directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of the Company in respect of the proposed transaction and any other matters to be voted on at the special meeting. Information about the Company and its directors and executive officers can be found in (i) the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, which was filed with the SEC on March 11, 2026, (ii) the Company’s proxy statement for its 2026 Annual Shareholders Meeting, which was filed with the SEC on April 7, 2026, and (iii) the Company’s other filings with the SEC, including any statements of beneficial ownership on Form 3, Form 4 or Form 5. Additional information regarding ownership of the Company’s securities by its directors and executive officers is included in such persons’ SEC filings on Forms 3 and 4. These documents may be obtained free of charge at http://www.sec.gov, the SEC’s website, or on the Company’s investor relations website (http://www.investors.mistrasgroup.com). Additional information regarding the interests of participants in the solicitation of proxies in connection with the proposed transaction will be included in the proxy statement that the Company expects to file in connection with the proposed transaction and other relevant materials the Company may file with the SEC.

No Offer or Solicitation

This communication is for information purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Forward-Looking and Cautionary Statements

Certain statements contained in this press release, including statements regarding the proposed transaction, are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally use words such as “future,” “possible,” “potential,” “targeted,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict,” “project,” “will,” “may,” “should,” “could,” “would” and other similar words and phrases. These forward-looking statements are based on the beliefs and assumptions of management at the time that these statements were prepared and are inherently uncertain. Such statements are not guarantees of future events or results and may not accurately indicate the timing of, or the date by which, such events or results will be consummated or achieved, if at all. These statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in these statements. Such risks, uncertainties and contingencies include, among others: uncertainties as to the timing of the proposed transaction; uncertainties as to how many of the Company’s stockholders will vote in favor of the proposed transaction including the possibility that the Company’s stockholders may not approve the proposed transaction; the possibility that competing offers will be made, whether through the “go-shop” process or otherwise; the ability to receive the required consents and regulatory approvals for the proposed transaction and to satisfy the other closing conditions of the proposed transaction on a timely basis or at all; the risk that, prior to the completion of the proposed transaction, the Company’s business and its relationships with employees, collaborators, vendors and other business partners could experience significant disruption due to transaction-related uncertainty; the risk that stockholder litigation in connection with the proposed transaction may result in significant costs of defense, indemnification and liability; negative effects of the announcement of the proposed transaction on the market price of the Company’s common stock and/or on the Company’s business, financial condition, results of operations and financial performance; the ability of the Company to retain and hire key personnel; and the risks and uncertainties pertaining to the Company’s business, including those detailed under “Risk Factors” and elsewhere in the Company’s public periodic filings with the SEC. There can be no assurance that the proposed transaction or any other transaction described above will in fact be consummated in the manner described or at all. Stockholders, potential investors and other readers are urged to consider these risks and uncertainties in evaluating forward-looking statements and are cautioned not to place undue reliance on the forward-looking statements. It is not possible to anticipate or foresee all risks and uncertainties, and investors should not consider any list of risks and uncertainties to be exhaustive or complete. For additional information on identifying factors that may cause actual results to vary from those stated in forward-looking statements, please see the Company’s statements and reports on Forms 10-K, 10-Q and 8-K filed with the SEC and other written statements made by the Company from time to time. Forward-looking statements speak only as of the date of this communication, and, except as required by applicable law, the Company does not undertake any obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.

MISTRAS Media Contact:

Theresa Feraren
Senior Vice President & Chief Marketing Officer
MISTRAS Group, Inc.
marcom@mistrasgroup.com

Aaron Palash / Tim Lynch
Joele Frank, Wilkinson Brimmer Katcher
+1 (212) 355-4449

MISTRAS Investors Contact:

Edward J. Prajzner
Senior Executive Vice President & Chief Financial Officer
+1 (833) MISTRAS | investors@mistrasgroup.com

H.I.G. Contact:

Media Relations
media@hig.com

LITTLE ROCK, Ark., Sept. 18, 2026 (GLOBE NEWSWIRE) — Dillard’s, Inc. (NYSE: DDS) (the “Company” or “Dillard’s”), a Texas corporation headquartered in Little Rock, Arkansas, today announced that it will voluntarily transfer the primary listings of its securities from the New York Stock Exchange (“NYSE”) to the Texas Stock Exchange (“TXSE”).

The transfer applies to both Dillard’s Class A Common Stock (ticker: DDS) and the 7.50% Capital Securities of Dillard’s Capital Trust I (and the Guarantee of the Company with respect thereto) (ticker: DDT). Both securities are expected to cease trading on the NYSE as primary listings at the market close on Friday, October 2, 2026, and commence trading on the TXSE as primary listings at the market open on Monday, October 5, 2026, retaining their existing ticker symbols. No action is required by DDS shareholders or DDT securityholders in connection with the transfer.  

The move aligns Dillard’s deep roots and strong retail presence in Texas with TXSE’s technology-driven platform. Dillard’s Texas heritage dates back to 1956, when founder William T. Dillard acquired a store in downtown Tyler. The Lone Star State has since grown into the Company’s largest market, now home to 54 locations. Dillard’s reincorporated from Delaware to Texas in August 2025.

About Dillard’s
Dillard’s was founded by William T. Dillard in 1938 in Nashville, Arkansas with an $8,000 investment in a hometown department store. Today, Dillard’s, Inc. ranks among the nation’s largest fashion retailers – operating 272 Dillard’s stores, including 28 clearance centers, spanning 30 states and an Internet store at dillards.com. The Company focuses on delivering style, quality and value to its customers by offering premium fashion apparel, beauty and home collections from both national and exclusive brand sources. Dillard’s complements this curated merchandise assortment with exceptional, client-focused customer care.

Forward-Looking Statements
Certain matters contained in this press release concerning the listing transfers of DDS and DDT constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon management’s expectations and beliefs concerning future events impacting the Company. Many factors outside the Company’s control, including risks related to delays in the timing for implementing the transfers, potential market disruptions with respect to the trading of the securities and potential impacts on the Company’s business or operations as it implements the transfers, could cause actual results to differ materially from those contemplated by forward-looking statements. Forward-looking statements speak only as of the date they were made, and the Company undertakes no obligation to publicly update them. For a description of other factors that could cause the Company’s future results to differ from those expressed in any such forward-looking statements, see Item 1A entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended January 31, 2026.

CONTACT:
Dillard’s, Inc.
Julie J. Guymon
501-376-5965
julie.guymon@dillards.com

  • Ocrevus addresses a critical need in paediatric neurology as the first high- efficacy anti-CD20 treatment option for people with MS as young as 10 years old 
  • In the Phase III OPERETTA 2 study, Ocrevus demonstrated non-inferiority in relapse control and superiority over fingolimod in suppressing brain lesions1
  • Safety in children and adolescents was aligned with the established safety profile of Ocrevus across more than 525,000 adult patients globally1

Basel, 18 September 2026 – Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Ocrevus® (ocrelizumab) intravenous (IV) infusion for the treatment of paediatric patients aged 10 years and older with relapsing forms of multiple sclerosis (RMS). The U.S. FDA approved Ocrevus for paediatric RMS patients in May 2026. A final decision from the European Commission is expected in the near future.

“Children and teens living with multiple sclerosis experience more frequent and severe relapses than adults, yet their treatment options have lagged behind,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “The positive CHMP opinion brings us closer to bridging a longstanding gap in Europe, offering young people with MS a high-efficacy therapy backed by a decade of adult experience.”

“Living with a paediatric MS diagnosis means that children and adolescents must navigate a complex condition with unpredictable relapses that require hospital admission and acute therapies, lead to missed days of school and social activities, and face the potential for future disability,” said Dr. Brenda Banwell, MD, Chair of Pediatrics, Johns Hopkins Medicine, Pediatrician-in-Chief and Co-Director, Johns Hopkins Children’s Center. “Extending Ocrevus, a proven treatment for adults, to younger patients is an important step forward to suppress disease activity early on, with the goal of preserving their physical and cognitive health.”

The CHMP’s positive opinion is based on the Phase III OPERETTA 2 study, which showed that Ocrevus was non-inferior to fingolimod (the current standard treatment in paediatric MS) at controlling relapses, reducing the risk of relapses by 48% compared with fingolimod. In OPERETTA 2, Ocrevus was superior at reducing brain inflammation, showing significant reductions in new or enlarging T2 lesions (-48%) and gadolinium-enhancing active T1 lesions (-87%). Ocrevus demonstrated a consistent safety profile in children and teens similar to that seen in adults, with no patients stopping treatment due to side effects.1

At least 40,000 children and adolescents are living with MS worldwide, with roughly one-third in Europe, emphasising the need for early high-efficacy MS treatment.2

About Ocrevus® (ocrelizumab)
Ocrevus is a humanised monoclonal antibody designed to target CD20-positive B cells, a specific type of immune cell thought to be a key contributor to myelin (nerve cell insulation and support) and axonal (nerve cell) damage. Ocrevus IV and Ocrevus subcutaneous (SC; marketed as Ocrevus Zunovo® [ocrelizumab hyaluronidase-ocsq] in the U.S.) are the only therapies approved for both RMS (including relapsing-remitting multiple sclerosis [RRMS] and active, secondary progressive multiple sclerosis [SPMS], as well as clinically isolated syndrome [CIS] in the U.S.) and primary progressive multiple sclerosis (PPMS). Both Ocrevus IV and SC are administered every six months. The initial IV dose is given as two 300 mg infusions two weeks apart with subsequent doses given as single 600 mg infusions. Ocrevus SC is given as a single 920 mg subcutaneous injection every six months.

About multiple sclerosis
Multiple sclerosis is a chronic disease that affects more than 3 million people worldwide. People with all forms of multiple sclerosis experience disease progression from the beginning of their disease. Therefore, an important goal of treating multiple sclerosis is to slow, stop and ideally prevent progression as early as possible.

Approximately 85% of people with multiple sclerosis are initially diagnosed with relapsing-remitting multiple sclerosis (RRMS). Relapsing forms of the disease (RMS) include RRMS and active secondary progressive MS, and people with RMS experience relapses and worsening disability over time. Primary progressive multiple sclerosis (PPMS) is a debilitating form of the disease marked by steadily worsening symptoms but typically without distinct relapses or periods of remission. Approximately 15% of people with multiple sclerosis are diagnosed with the primary progressive form of the disease. Until the FDA approval of Ocrevus®, there had been no FDA-approved treatments for PPMS, and Ocrevus is still the only approved treatment for PPMS. Despite the availability of high-efficacy therapies, over a third of MS patients remain on lower-efficacy therapy today. Slowing or stopping progression while simultaneously stopping relapses remains a high unmet need in MS.

About Roche in Neurology
Neurology is a major focus of research and development at Roche. Our goal is to pursue groundbreaking science to develop new diagnostics and treatments that help improve the lives of people with chronic and potentially devastating diseases globally.

Roche is investigating more than a dozen medicines for neurological conditions, including multiple sclerosis, spinal muscular atrophy, neuromyelitis optica spectrum disorder, Alzheimer’s disease, Huntington’s disease, Parkinson’s disease and Duchenne muscular dystrophy. Roche Diagnostics has developed a broad range of approved and investigational tools, including digital and blood-based tests and cerebrospinal fluid (CSF) assays, aiming to more effectively detect, diagnose and monitor neurological conditions. Together with our partners, we are committed to pushing the boundaries of scientific understanding to solve some of the most difficult challenges in neurology today.

About Roche
Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions.

Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them.

Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References
[1] Banwell B, et al. Efficacy and Safety of Ocrelizumab Compared With Fingolimod in Paediatric Relapsing- Remitting MS: Results of the Phase III OPERETTA 2 Study. Presented at the 2025 Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 26 September 2025; Barcelona, Spain. 
[2] MS International Federation. The Atlas of MS 2026: A global update on MS prevalence, incidence, and the gaps that remain. September 2026. Available from: http://www.msif.org/wp-content/uploads/2026/09/Atlas-Epidemiology-report-text-core-data-2026-FINAL.pdf

Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Tristan Schmitz
Phone: +41 79 529 70 35
Lorena Corfas
Phone: +41 79 568 24 95

 

Simon Goldsborough
Phone: +44 797 32 72 915
Karsten Kleine
Phone: +41 79 461 86 83

 

Kirti Pandey
Phone: +41 79 398 38 53
Yvette Petillon
Phone: +41 79 961 92 50

 

Irène Stephan
Phone:  +41 79 377 83 75
Albert Thottiyil
Phone: +41 79 775 66 12

Attachment

If approved, Sogroya® (somapacitan) would be the first and only growth hormone treatment approved for idiopathic short stature in the EU, providing a much-needed treatment option for children and their families affected by this condition.

  • The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended once-weekly Sogroya® (somapacitan) for children in Europe living with idiopathic short stature (ISS) with persistent growth disturbance.
    • ISS is a diagnosis given to children who are significantly shorter than their peers when no underlying medical cause can be found, affecting a child’s confidence and well-being1-4. This affects up to 3% of children worldwide1,6,8.
    • Positive opinion follows the previous recommendation for Sogroya® in the treatment of short stature in children born Small for Gestational Age (SGA) and with Noonan Syndrome (NS) in Europe5.

Bagsværd, Denmark, 18 September 2026 – Novo Nordisk today welcomed a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), recommending once-weekly Sogroya® for children with idiopathic short stature (ISS) with persistent growth disturbance.

“Through our research and relationships with the community, we know that 70% of families raising children with ISS and other growth disorders feel unseen, and that the impact on their child’s daily life simply isn’t recognised,” said Ashley Gilmer, chief executive officer of International Coalition of Organizations Supporting Endocrine Patients (ICOSEP). “This recommendation is a meaningful signal that this may be starting to change. What matters now is that recognition turns into real support of timely diagnosis, clear information, and access to care for every family who needs it.”

ISS affects up to 3% of children worldwide, yet it remains under-recognised and has limited options for managing its treatment1,6-8. As part of the REAL8 clinical trial, Sogroya® has been assessed for the treatment of ISS and acts as a long-acting growth hormone, given as a single injection under the skin once a week9,10. If approved, Sogroya® would be the first and only growth hormone treatment approved for ISS in the EU, providing a much-needed treatment option for children and their families living with this condition.

“For too long, treatment options for many children with growth disorders have been limited. Building on our decades of experience in growth hormone medicines, we’re committed to changing that. Today’s approval recommendation from the CHMP is a very important step forward for children and their families affected by ISS across Europe,” said Martin Holst Lange, executive vice president, chief scientific officer and head of Research & Development at Novo.

This opinion follows the CHMP recommendation of Sogroya® for the treatment of short stature in children born small for gestational age (SGA) and Noonan Syndrome (NS) in May 20265. The opinion is now passed to the European Commission, whose decision on marketing authorisation, covering all three indications, is expected later this year.

About once-weekly Sogroya® (somapacitan)

Once-weekly Sogroya® (somapacitan) is a long-acting human growth hormone analogue, given as a single injection under the skin once a week. It uses albumin-binding technology, which allows the growth hormone to attach to a protein naturally present in the blood, allowing it to remain in the body for longer11.

In the EU, Sogroya® was authorised for the treatment of growth hormone deficiency in adults on 31 March 2021 and in children aged 3 years and older on 24 July 202312.

The REAL8 clinical trial data that supported this positive CHMP opinion showed that once-weekly Sogroya® was non-inferior to once-daily growth hormone treatment for mean annualised height velocity at Week 52 in children with idiopathic short stature, born small for gestational age and Noonan Syndrome9.

What is idiopathic short stature?

Idiopathic short stature is a diagnosis given to children who are significantly shorter than their peers when no underlying medical cause can be found1. It affects up to 3% of children worldwide, yet it remains under-recognised and often overlooked – in many countries, it is not a recognised condition1,6,7. Children with idiopathic short stature are more likely to face teasing, bullying and social exclusion as a result of their condition – experiences that can affect confidence and wellbeing into adulthood2,3,13.

Why is idiopathic short stature difficult to diagnose and treat?
The path to a diagnosis is often long and emotionally draining for families, as it can only be identified once other causes of short stature have been ruled out14. As many children with idiopathic short stature are not referred for diagnosis until puberty is approaching, the window for effective intervention with growth hormone (GH) therapy is limited15,16. Even after diagnosis, treatment with GH therapy is only approved for idiopathic short stature in some regions and used off-label or not at all in others, leaving many children and families without options14,17,18.

What does it mean to be born small for gestational age?

When a baby is born small for gestational age, it means they are smaller than expected in length, weight, or head circumference19,20. There is not always a clear cause, though being born small for gestational age has been associated with genetic factors, problems with the placenta and maternal health, including malnutrition, chronic high blood pressure and chronic infections21. Most children born small for gestational age reach their expected height by the age of two, but if catch-up growth has not happened by two or three years of age, a referral to a paediatric endocrinologist may be needed22,23.

What is Noonan Syndrome?
Noonan Syndrome is a genetic condition affecting both boys and girls, occurring in around 1 in 1,000 to 2,500 births24,25. Around half of all cases are caused by a mutation on a gene found on chromosome 1225. Noonan Syndrome can have a variety of effects on a child’s health and development, including short stature, heart defects present at birth, and certain distinctive facial features24.

Novo is the global healthcare company that believes lasting health starts now. For over a century, we’ve combined leading scientific expertise with a deep understanding of people’s lives. We develop treatments and support that help millions of people make progress they can see, feel and sustain now and in the future. Every day, over 67,000 employees around the world advance our purpose to drive change for lasting health. Through our partnerships, programmes and investments, we’re working to prevent disease, expand access to treatments and reduce our environmental impact to help even more people live healthier lives. For more information, visit novonordisk.com and follow us on Instagram, LinkedIn, TikTok, Facebook, X and YouTube.

Contacts for further information

Novo Media:  
Ambre James-Brown
+45 3079 9289
globalmedia@novonordisk.com

Liz Skrbkova (US)
+1 609 917 0632
USMediaRelations@novonordisk.com

Novo Investors:  
Michael Novod
+45 3075 6050
nvno@novonordisk.com

Sina Meyer
+45 3079 6656
azey@novonordisk.com

Christoffer Togo Solgaard-Tullin
+45 3079 1471
cftu@novonordisk.com

 
Ida Schaap Melvold
+45 3077 5649
idmg@novonordisk.com

Mads Berner Bruun
+45 3075 2936
mbbz@novonordisk.com

Frederik Taylor Pitter (US)
+1 609 613 0568
fptr@novonordisk.com

Alex Bruce (US)
+1 640 230 0276
axeu@novonordisk.com

References

1.      Wit JM, Clayton PE, Rogol AD, et al. Idiopathic short stature: definition, epidemiology, and diagnostic evaluation. Growth Horm IGF Res. 2008;18:89-110.
2.      A Juul, A Linglart, MH Rasmussen, et al. Impact of Idiopathic Short Stature (ISS) on children’s well-being. ESPE Abstracts (2024), 98, P1-68. Paper/Poster presented.
3.      Novo Nordisk Data on File. Equips: Evaluating the Quality of Life in People with Short Stature. 2025.
4.      The Magic Foundation. Psycological impact of short stature on children and adolescents [online]. Available at: magicfoundation.org/psychologicalimpact. Last accessed: August 2026.
5.      Sogroya – opinion on variation to marketing authorisation. European Medicines Agency [online]. Available at: ema.europa.eu/en/medicines/human/variation/sogroya. Last accessed: August 2026.
6.      Sharma L, Rani D, Kanchan T, et al. Short Stature StatPearls Treasure Island (FL); 2026.
7.      Novo Nordisk Data on File. Investigating the Association between Idiopathic Short Stature and Health and Well-being: a register study. 2025.
8.      Romero CJ and Rapaport R. The challenges of optimising the treatment of children diagnosed with idiopathic short stature. Ann Hum Biol. 2026;53:2621718.
9.      Once-weekly Sogroya® (somapacitan) is an efficacious and welltolerated long-acting growth hormone in children with growth disorders: results from REAL8 phase 3 basket study presented at the joint Congress of ESPE and ESE 2025. Novo Nordisk [online]. Available at: ml-eu.globenewswire.com/Resource/Download/f899ae3b-aa4e-4ef3-9498-9537d9cc424b. Last accessed: August 2026.
10.      Sogroya® (somapacitan): SmPC [online]. Available at: ema.europa.eu/en/documents/product-information/sogroya-epar-product-information_en.pdf. Last accessed: August 2026.
11.      Johansson E, Nielsen AD, Demuth H, et al. Identification of Binding Sites on Human Serum Albumin for Somapacitan, a Long-Acting Growth Hormone Derivative. Biochemistry. 2020;59:1410-1419.
12.      An overview of Sogroya and why it is authorised in the EU. European Medicines Agency [online]. Available at: ema.europa.eu/en/documents/overview/sogroya-epar-medicine-overview_en.pdf. Last accessed: August 2026.
13.      Investigating the Association between Idiopathic Short Stature and Health and Well-being: a register study. 2025.
14.      Pedicelli S PE, Violi E, et al. Controversies in the definition and treatment of idiopathic short stature (ISS). J Clin Res Pediatr Endocrinol. 2009;1:105-115.
15.      Cohen P, Rogol AD, Deal CL, et al. Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J Clin Endocrinol Metab. 2008;93:4210-7.
16.      Novo Nordisk Data on File. Adivo – 2023 US GHT Patient Assessment. 2025.
17.      Kemp SF and Frindik JP. Emerging options in growth hormone therapy: an update. Drug Des Devel Ther. 2011;5:411-9.
18.      Murano MC. A Disability Bioethics Reading of the FDA and EMA Evaluations on the Marketing Authorisation of Growth Hormone for Idiopathic Short Stature Children. Health Care Anal. 2020;28:266-282.
19.      Schlaudecker EP, Munoz FM, Bardaji A, et al. Small for gestational age: Case definition & guidelines for data collection, analysis, and presentation of maternal immunisation safety data. Vaccine. 2017;35:6518-6528.
20.      Lee PA, Chernausek SD, Hokken-Koelega AC, et al. International Small for Gestational Age Advisory Board consensus development conference statement: management of short children born small for gestational age, April 24-October 1, 2001. Pediatrics. 2003;111:1253-61.
21.      Liu Q, Yang H, Sun X, et al. Risk factors and complications of small for gestational age. Pak J Med Sci. 2019;35:1199-1203.
22.      Finken MJJ, van der Steen M, Smeets CCJ, et al. Children Born Small for Gestational Age: Differential Diagnosis, Molecular Genetic Evaluation, and Implications. Endocr Rev. 2018;39:851-894.
23.      Hokken-Koelega ACS, van der Steen M, Boguszewski MCS, et al. International Consensus Guideline on Small for Gestational Age: Etiology and Management From Infancy to Early Adulthood. Endocr Rev. 2023;44:539-565.
24.      Sharma L, Winters R and Corado A. Noonan Syndrome StatPearls Treasure Island (FL); 2026.
25.      Visser-van Balen H, Sinnema G and Geenen R. Growing up with idiopathic short stature: psychosocial development and hormone treatment; a critical review. Arch Dis Child. 2006;91:433-9.

Attachment

These Relevant Opportunities Are Valued in the Hundreds of Millions of Dollars

Newport Beach, CA, Sept. 18, 2026 (GLOBE NEWSWIRE) — Bimergen Energy Corporation (NYSE American: BESS), a developer, owner, and operator of utility-scale and distributed battery energy storage systems, today announced that its wholly owned subsidiary, Emergen Energy, LLC, has completed its System for Award Management (SAM.gov) registration and received its Commercial and Government Entity (CAGE) code 23R51. Emergen’s registration is active for “All Awards,” establishing the registration foundation to compete for federal contracts and pursue eligible federal assistance opportunities, subject to individual solicitation and program requirements.

The milestone supports Bimergen’s strategy of expanding the commercial reach of its energy storage development capabilities and building relationships that advance energy infrastructure projects. With an active federal registration, Emergen is positioned to pursue opportunities with government agencies and explore collaboration with prime contractors and other industry partners.

Assigned by the Defense Logistics Agency, the CAGE code identifies Emergen within federal procurement systems. The combination of active SAM.gov registration and CAGE code assignment completes a foundational step in the Company’s preparation to participate in the federal marketplace.

“Completing our federal registration is a meaningful step in expanding the opportunities available to Bimergen,” said Cole Johnson, Co-CEO of Bimergen Energy. “Our focus is on developing energy storage infrastructure that strengthens grid reliability and delivers flexible power when needed. We now have the registration foundation to pursue federal opportunities aligned with those capabilities and build relationships with government customers and industry partners.”

Bimergen’s growth strategy combines battery energy storage development with technology and capital partnerships designed to advance projects toward construction and operation. Participation in the federal marketplace offers a potential additional customer channel that complements the Company’s activities across U.S. power markets and its focus on reliable, resilient energy infrastructure.

“Our strategy is to convert development capabilities and strong partnerships into long-term shareholder value,” said Bob Brilon, Co-CEO of Bimergen Energy. “Active SAM.gov registration broadens the opportunities related to hundreds of millions of government contract dollars that we can pursue as we grow our business. We see federal contracting as a potential extension of our commercial strategy, with an emphasis on opportunities that fit our capabilities and support disciplined growth.”

The registration milestone builds on Bimergen’s ongoing efforts to expand its market presence, advance its energy storage portfolio, and establish partnerships that support project execution. The Company remains focused on matching development opportunities with the technology, capital, and operational resources needed to create lasting value.

About Bimergen Energy Corporation

Bimergen Energy Corporation (NYSE American: BESS) is a U.S.-based energy infrastructure developer, asset owner, and operator focused on utility-scale and distributed battery energy storage systems (BESS). The Company develops projects designed to enhance grid reliability, support renewable energy integration, and provide flexible energy solutions across key U.S. power markets. Bimergen works with technology providers and capital partners to advance projects through development, construction, and long-term operation.

For more information about Bimergen Energy, please visit www.bimergen.com.

Forward-Looking Statements

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. These statements include expectations regarding federal contracting and assistance opportunities, potential customer and market expansion, project development, strategic partnerships, and long-term shareholder value. Forward-looking statements may be identified by words such as “believe,” “expect,” “intend,” “may,” “plan,” “potential,” “seek,” and similar expressions.

Forward-looking statements are based on Bimergen Energy Corporation’s current expectations and assumptions. Actual results may differ materially due to factors including procurement requirements and award decisions, competition, financing availability, regulatory approvals, project execution, and other risks described in the Company’s Annual Report on Form 10-K and subsequent filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date of this announcement. Bimergen Energy Corporation undertakes no obligation to update these statements except as required by applicable law.

Media Contact:
Dave Gentry
RedChip Companies Inc.
1-407-644-4256 | 1-800-REDCHIP (733-2447)
BESS@redchip.com

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 18, 2026 (GLOBE NEWSWIRE) — CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced that it has entered into a partnership with QIMA Life Sciences, a world leading preclinical dermatology CRO, to explore the potential of several of CDT’s assets in autoimmune skin diseases.

CDT plans to leverage QIMA’s unique access to human skin from both healthy donors and patients. The use of patient tissue offers the most clinically relevant data possible, providing rapid translation to clinic and providing potential license partners the highest level of confidence possible for clinical success.

Initial studies will be centred around tapinarof (VTAMA®), a drug currently approved for plaque psoriasis and atopic dermatitis in the US and Japan. CDT has created a robust intellectual property portfolio around tapinarof, including solid form and method-of-use patents in combination with other known drugs. QIMA will explore the potential of these novel combinations in psoriatic patient skin, with the aim of working towards a second generation tapinarof product with increased efficacy and patient benefits. VTAMA® is currently the number one branded topical treatment in the US, and CDT believe that developing a combination therapy could both expand, and extend, its market to further patient groups.

CDT also plans to investigate the potential of its proprietary tapinarof combinations in vitiligo, an autoimmune disease often associated with significant emotional and psychological distress for sufferers. Vitiligo is a common chronic autoimmune disorder affecting approximately 0.5%–2.0% of the global population, representing tens of millions of patients worldwide1. The global vitiligo drug market was estimated at approximately US$2.6 billion in 2025 and is projected to reach US$6.6 billion by 20302. Current approved treatments often prove intolerable for many patients, especially pediatric patients, and re-pigmentation can take a considerable amount of time, demonstrating a significant unmet need for new therapies that are effective, yet tolerable. Working with human skin will allow CDT to explore the potential of these combinations in the most physiologically relevant setting possible.

For further information or to discuss potential partnership opportunities, please contact the Company at info@cdtequity.com.

About QIMA Life Sciences

QIMA Life Sciences is a contract research organization specializing in cellular and molecular pharmacology. It partners with pharmaceutical and biotechnology companies to advance research and accelerate drug development through tailored, science-driven solutions spanning early discovery through clinical development. By combining preclinical and clinical research and testing solutions with advanced AI-driven image analysis and digital data platforms, QIMA Life Sciences enables companies to generate the robust scientific evidence needed to bring innovative drugs to patients with confidence. www.qima-lifesciences.com

About CDT Equity Inc.

CDT Equity Inc. (NASDAQ: CDT) is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. Originally established as Conduit Pharmaceuticals, the company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. Looking ahead, CDT are committed to creating shareholder value through licensing, strategic M&A, and positioning the company as a platform for transformative innovation.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release, including statements regarding CDT’s future results of operations and financial position, CDT’s business strategy, prospective product candidates, product approvals, research and development cost timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated studies and business endeavors with third parties, and future results of current and anticipated product candidates, are forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to; the effect that the reverse stock split may have on the price of the Company’s common stock; the ability or inability to maintain the listing of CDT’s securities on Nasdaq; the ability to recognize the anticipated benefits of the business combination completed in September 2023, which may be affected by, among other things, competition; the ability of the combined company to grow and manage growth economically and hire and retain key employees; the risks that CDT’s product candidates in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities on a timely basis or at all; changes in applicable laws or regulations; the possibility that CDT may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties identified in other filings made by CDT with the U.S. Securities and Exchange Commission. Moreover, CDT operates in a very competitive and rapidly changing environment. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond CDT’s control, you should not rely on these forward-looking statements as predictions of future events.

Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, CDT assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. CDT gives no assurance that it will achieve its expectations.

Investors
CDT Equity Inc.
Info@cdtequity.com

__________________________
1 https://onlinelibrary.wiley.com/doi/full/10.1002/ski2.317
2 https://www1.hkexnews.hk/app/sehk/2026/108643/documents/sehk26061501863.pdf

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.